Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

PURPOSE: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known. PATIENTS AND METHODS: In a 12-month stud...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Michaelson, M. Dror, Kaufman, Donald S., Lee, Hang, McGovern, Francis J., Kantoff, Philip W., Fallon, Mary Anne, Finkelstein, Joel S., Smith, Matthew R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2007
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047397/
https://ncbi.nlm.nih.gov/pubmed/17369566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2006.07.3361
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi